{"entity":{"type":"insider","cik":"0001824631","url":"/insider/0001824631","json_url":"/insider/0001824631.json","name":"Pierce Christopher","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":5,"first":"2020-09-29","last":"2021-09-07","span_basis":"filed_date"},"name_variants":[{"name":"Pierce Christopher","source":"filing","n_filings":5,"first_seen":"2020-09-29","last_seen":"2021-09-07"}],"transactions":[{"id":5103146,"accession":"0001209191-21-055072","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-055072","line_url":"/filing/0001209191-21-055072","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001824631","owner_name":"Pierce Christopher","owner_display_name":"Pierce Christopher","owner_url":"/insider/0001824631","role":"Officer (EVP and Chief of Business Oper)","role_mark":"O","role_mark_label":"Officer (EVP and Chief of Business Oper)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief of Business Oper","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":41.67604128235294,"price_display":"41.68","price_state":"stated","total_value":708492.7018,"total_display":"708,492.70","total_whole":"708,493","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-02","filed_date":"2021-09-07","scope":"insider","n_lines":3},{"id":5490673,"accession":"0001209191-21-029352","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-029352","line_url":"/filing/0001209191-21-029352#line-2","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001824631","owner_name":"Pierce Christopher","owner_display_name":"Pierce Christopher","owner_url":"/insider/0001824631","role":"Officer (EVP and Chief of Business Oper)","role_mark":"O","role_mark_label":"Officer (EVP and Chief of Business Oper)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief of Business Oper","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3295.0,"shares_display":"3,295","price_per_share":40.2928,"price_display":"40.29","price_state":"stated","total_value":132764.776,"total_display":"132,764.78","total_whole":"132,765","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-29","filed_date":"2021-04-30","scope":"insider"},{"id":4569157,"accession":"0001209191-21-026874","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-026874","line_url":"/filing/0001209191-21-026874#line-2","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001824631","owner_name":"Pierce Christopher","owner_display_name":"Pierce Christopher","owner_url":"/insider/0001824631","role":"Officer (EVP and Chief of Business Oper)","role_mark":"O","role_mark_label":"Officer (EVP and Chief of Business Oper)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief of Business Oper","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":8000.0,"total_display":"8,000.00","total_whole":"8,000","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-08","filed_date":"2021-04-15","scope":"insider"},{"id":4529521,"accession":"0001209191-21-026293","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-026293","line_url":"/filing/0001209191-21-026293#line-2","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001824631","owner_name":"Pierce Christopher","owner_display_name":"Pierce Christopher","owner_url":"/insider/0001824631","role":"Officer (EVP and Chief of Business Oper)","role_mark":"O","role_mark_label":"Officer (EVP and Chief of Business Oper)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief of Business Oper","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":828.0,"shares_display":"828","price_per_share":40.0826,"price_display":"40.08","price_state":"stated","total_value":33188.3928,"total_display":"33,188.39","total_whole":"33,188","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-07","filed_date":"2021-04-09","scope":"insider"},{"id":3046920,"accession":"0001209191-20-052400","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-052400","line_url":"/filing/0001209191-20-052400#line-1","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001824631","owner_name":"Pierce Christopher","owner_display_name":"Pierce Christopher","owner_url":"/insider/0001824631","role":"Officer (EVP and Chief of Business Oper)","role_mark":"O","role_mark_label":"Officer (EVP and Chief of Business Oper)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief of Business Oper","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3750.0,"shares_display":"3,750","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":71250.0,"total_display":"71,250.00","total_whole":"71,250","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-29","filed_date":"2020-09-29","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":7,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":7},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001678660","name":"Prelude Therapeutics Inc","url":"/issuer/0001678660","role":"Officer (EVP and Chief of Business Oper)","n_filings":5,"first_seen":"2020-09-29","last_seen":"2021-09-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001824631","retrieved_at":"2026-08-26T17:37:47+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}